BridgeBio Pharma (NASDAQ: BBIO) holder files to sell 120,000 shares

Rhea-AI Filing Summary

A holder of BridgeBio Pharma (BBIO) common stock filed a notice of intent to sell 120,000 shares under Rule 144. The shares are common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,912,400 and 192,708,813 common shares outstanding. The seller originally acquired these 120,000 shares on 03/26/2016 via conversion of management incentive units from the issuer.

The filing also lists recent sales made under Rule 10b5-1 trading plans over the prior three months by Neil Kumar and related trusts. Examples include 30,011 common shares sold on 12/15/2025 for gross proceeds of $2,239,901.00, and 20,000-share transactions on multiple dates in November and October 2025 by revocable and irrevocable trusts associated with the same address. The signer represents they are not aware of undisclosed material adverse information about the issuer.

Insights

Equity capital markets analyst

Rule 144 filing discloses a planned 120,000-share sale and prior 10b5-1 sales.

This notice shows a holder of BridgeBio Pharma (BBIO) common stock planning to sell 120,000 shares through Morgan Stanley’s executive financial services group. The shares were acquired on 03/26/2016 via conversion of management incentive units, indicating they stem from equity compensation rather than open-market purchases. With common shares outstanding at 192,708,813, the filing documents compliance with Rule 144 resale requirements.

The document also details recent Rule 10b5-1 plan activity over the prior three months for Neil Kumar and associated revocable and irrevocable trusts. Individual line items include, for example, 30,011 shares sold on 12/15/2025 for gross proceeds of $2,239,901.00. Because these are structured, pre-arranged trading plans, actual market impact depends on execution over time rather than any single transaction disclosed here.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	120000	8912400.00	192708813	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/26/2016	Conversion Management Incentive Units	Issuer			120000	03/26/2016	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	12/15/2025	30011	2239901.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	12/05/2025	20000	1466288.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	12/05/2025	20000	1466276.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	12/04/2025	20000	1487954.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	12/04/2025	20000	1487958.00
10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	11/20/2025	26156	1722223.51
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	11/07/2025	20000	1228478.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	11/07/2025	20000	1228514.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	11/06/2025	20000	1263020.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	11/06/2025	20000	1263096.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	10/09/2025	20000	1096046.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	10/09/2025	20000	1096046.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BBIO Rule 144 filing disclose about planned share sales?

The filing shows a holder of BridgeBio Pharma (BBIO) common stock intends to sell 120,000 shares of common stock through Morgan Stanley Smith Barney LLC under Rule 144.

How many BridgeBio Pharma (BBIO) shares are outstanding in this notice?

The notice states that 192,708,813 shares of BridgeBio Pharma common stock were outstanding at the time referenced.

How were the 120,000 BBIO shares being sold under Rule 144 originally acquired?

The 120,000 shares were acquired on 03/26/2016 through a conversion of management incentive units from the issuer.

Which broker is handling the planned sale of BBIO shares in this filing?

The planned sale of 120,000 BridgeBio Pharma common shares is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services.

What recent 10b5-1 sales related to BBIO are listed in the past 3 months section?

The filing lists multiple Rule 10b5-1 sales, including 30,011 BBIO common shares sold for $2,239,901.00 on 12/15/2025 for Neil Kumar and several 20,000-share transactions in October and November 2025 by revocable and irrevocable trusts at the same Palo Alto address.

What representation does the seller make about BridgeBio Pharma information?

By signing, the seller represents that they do not know any material adverse information about BridgeBio Pharma’s current or prospective operations that has not been publicly disclosed.